All the sessions from Transform 2021 are available on-demand now. Watch now. Proceeds will support clinical and commercial efforts for lead asset BRIMOCHOL™ under investigation for presbyopia as well as new research and development activities in the Company’s drug development pipeline Strengthens its Board of Directors with the addition of John de Koning of LSP, […]
Home »
ImmunoMet Therapeutics Granted Fast Track Designation by U.S. FDA for IM156 in Idiopathic Pulmonary Fibrosis
Join Transform 2021 this July 12-16. Register for the AI event of the year. HOUSTON–(BUSINESS WIRE)–May 3, 2021– ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead compound IM156, […]
ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing
– Phase 1 clinical study recruitment in healthy volunteers is expected to start in Q1 2021 – – Pre-clinical studies have demonstrated a strong anti-fibrotic effect in animal models of fibrosis – – Recently completed Phase 1 trial in oncology patients demonstrated good safety profile – HOUSTON–(BUSINESS WIRE)–February 8, 2021– ImmunoMet Therapeutics, Inc., a clinical […]
ONK Therapeutics Closes New Financing and Appoints Chris Nowers as CEO
Off-the-shelf natural killer cell therapy company, targeting solid and hematological cancers Raises US$8M from US-based investor Acorn Bioventures and current shareholders, bringing total raised in last six months to US$14.6M Funding will enable expansion of R&D and manufacturing capabilities, and progression of its two lead programs towards the clinic: ONKT101 a dual-targeted NK cell therapy […]